NuProbe

NuProbe prototypes and validates high-sensitivity genomics panels for difficult DNA biomarkers including CNVs, gene fusions, and low-frequency mutations.

[NuProbe @Nu_Probe]

Achieve increased sensitivity for detecting & monitoring DNA mutations, gene fusions, & CNVs with a custom research assay for oncology biomarkers. Learn about our development services for biopharma & research applications at https://t.co/0NIeruqh85

[NuProbe @Nu_Probe]

Achieve increased sensitivity for detecting & monitoring DNA mutations, gene fusions, & CNVs with a custom research assay for oncology biomarkers. Learn about our development services for biopharma & research applications at https://t.co/0NIeruqh85

[NuProbe @Nu_Probe]

Visit our website to see how we can help you access highly sensitive assays to address unmet research needs for non-invasive detection and monitoring of oncology DNA biomarkers  https://t.co/0NIeruqh85

[NuProbe @Nu_Probe]

Create a custom research assay compatible with cfDNA, tumor tissue, or genomic DNA for detection of SNVs and indels, gene fusions, or CNVs utilizing one of our proprietary NGS or PCR technologies.

[NuProbe @Nu_Probe]

Data in this research shows by incorporating our proprietary technologies, we've been able to increase multiplexing capabilities by improving primer dimer formation. Review the digital copy at https://t.co/piAYTPIBgW #ASCO23

[NuProbe @Nu_Probe]

Is your team looking for a way to target rare biomarkers for exploratory & retrospective studies?

Stop by booth 2087 to get information on our high-sensitivity research assay capabilities & to grab a printed copy of our accepted abstracts for MRD in AML research. #ASCO23

[NuProbe @Nu_Probe]

Our team will be attending #ASCO23 this week. Visit us at booth 2087 to discuss how NuProbe’s research technologies could help your team improve the limit of detection for low-frequency mutations, gene fusions, and CNVs.

[NuProbe @Nu_Probe]

Learn how BDA can be an effective way to detect low-frequency mutations using equipment already in many laboratories https://t.co/Rr9IaPWx7W

[NuProbe @Nu_Probe]

In collaboration with @ClevelandClinicMD research demonstrated concordance of NuProbe’s BDA technology to NGS & ddPCR for the detection of a JAK2 mutation.

[NuProbe @Nu_Probe]

Join us today at 3 pm as we discuss BDA technology & highlight recent applications in oncology research, including detection of MRD in NPM1+ AML & KMT2A-rearranged AML & introduce a BDA qPCR research assay for detection of MSI without the need for a matched normal #AACR23

[NuProbe @Nu_Probe]

Meet one of our experts during the Exhibitor Spotlight Theater Presentation tomorrow – Theater D at 3 pm – and hear about NuProbe’s rare allele enrichment technology with the potential to improve nucleic acid biomarker detection across broad oncology applications #AACR23

[NuProbe @Nu_Probe]

Enable identification of low-frequency gene fusions – in a recent collaboration we designed an RUO NGS panel to detect KMT2A rearrangements at low frequencies w/out knowledge of exact fusions & breakpoints. Review a copy of these findings https://t.co/5876Io4C3r #AACR23

[NuProbe @Nu_Probe]

Access rapid custom assay development to support research studies & biomarker development programs that obtain improved detection of heme oncology biomarkers.

See how we applied our QBDA technology in a retrospective study using clinical samples from AML patients at #AACR23

[NuProbe @Nu_Probe]

Plus, join us during our spotlight theater presentation on April 18th where Nicholas Gallerani, PhD will take a deep dive into NuProbe’s Blocker Displacement Amplification technology & highlight applications for research cancer monitoring. #AACR23

[NuProbe @Nu_Probe]

Is your team looking for a way to improve the LoD for low-frequency mutations, gene fusions, and CNVs?

Explore our research technologies for oncology biomarker detection & monitoring at #AACR23. Visit our team to get info on our high-sensitivity research assay capabilities.

[NuProbe @Nu_Probe]

STARTING SOON: Join us at 1:00 pm in Track A to review Blocker Displacement Amplification, a rare allele enrichment technology with the potential to improve mutation detection from #LiquidBiopsy. #MRD

[NuProbe @Nu_Probe]

If you want to detect low frequency #GeneFusions, connect with our team in booth 8 at the Liquid Biopsy for Precision Oncology Summit

For Research Use Only. Not for use in diagnostic procedures.

[NuProbe @Nu_Probe]

Nick Gallerani, PhD, will be at the 7th Annual Liquid Biopsy for Precision Oncology Summit discussing the emergence of MRD as a biomarker in AML and the current challenges for MRD detection. Join the conversation Feb 15th #MRD

[NuProbe @Nu_Probe]

We’re privileged to work with a remarkable group of individuals. Today we celebrate the talented group of women who are an important part of our team. Your achievements have helped shape our research technologies and research efforts.
#WomenInScienceDay #WomenInScience

[NuProbe @Nu_Probe]

Attending the 7th Annual Liquid Biopsy for Precision Oncology Summit? Visit our team to discuss how we’ve utilized our BDA research technology to design an AML #MRD research assay to improve detection of low-frequency mutations https://t.co/GV0USYraDS
2023/